Posts

Posted on

Xtant Medical Announces Expiration of Rights Offering

BELGRADE, Mont., Dec. 07, 2020 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the subscription period for its previously announced rights offering of shares of the Company’s common stock at a subscription price of $1.07 per share expired on December 4, 2020, and these rights are no longer exercisable.

Based on a review of preliminary results provided by the Company’s subscription agent, EQ Shareowner Services, the Company expects to issue approximately 711,143 shares of common stock in the rights offering. The Company expects to receive gross proceeds of approximately $761,000 from the rights offering. The results of the rights offering and the Company’s estimates regarding the gross proceeds of the rights offering are preliminary and subject to finalization and verification by its subscription agent.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock issuable in the rights offering, nor will there be any sale of such common stock in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The Company’s registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on November 3, 2020. The registration statement, the prospectus dated November 5, 2020, and all of the Company’s SEC filings may be found on the SEC’s website at http://www.sec.gov.

About Xtant
Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant’s people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Caution
ary Statement
Regarding Forward-
L
ooking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “future,” “will,” “may,” “continue,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations regarding the final results of and the anticipated gross proceeds from the rights offering. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainties surrounding the results of the rights offering; the effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by subsequent disclosures in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 and in future Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David Carey
Lazar FINN
Ph: 212-867-1762
Email: [email protected]



Posted on

Dogness Announces OEM Order from International Pet Specialty Retailer

DONGGUAN, China, Dec. 07, 2020 (GLOBE NEWSWIRE) — Dogness International Corporation (“Dogness” or the “Company”) (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, announced an OEM order for certain pet products including harnesses and leashes, expected to be valued at $4 million. The customer is one of the world’s largest small format pet specialty retailers, with more than 600 stores around the world.

Revenue will be recognized upon shipment, with an initial shipment expected to occur over the next two weeks and the balance shipped during calendar year 2021. The Company anticipates recognizing the majority of sales during the fiscal year ending June 30, 2021.

Silong Chen, Chairman and Chief Executive Officer of Dogness, commented, “This is another major win for us and underscores our business momentum, the attractiveness of our broad line of high-quality pet products, and the effectiveness of our sales and marketing teams. We implemented a more aggressive strategy in order to capture a greater share of the opportunities we are seeing. We believe the pet market is in a period of sustained expansion, as we benefit from positive tailwinds from COVID-19 driving increased pet ownership, along with a shift in demographics to owners with higher disposable income that are prioritizing pet ownership and spending on their pets. These trends bode well for our business given our market leadership, commitment to innovation and strong distribution and partner network.”

About
Dogn
ess
Dogness (International) Corporation was born in 2003 from the belief that pet dogs and cats are important, well-loved family members. Through its smart products, hygiene products, health and wellness products, and leash products, Dogness is able to simplify pet lifestyles, make them more scientific, and enhance the relationship between pets and pet caregivers. The Company ensures industry-leading quality through its fully integrated vertical supply chain and world-class research and development capabilities, which has resulted in over 200 patents and patents pending. Dogness products reach families worldwide through global chain stores and distributors. For more information, please visit: ir.dogness.com.

Forward Looking Statements
No statement made in this press release should be interpreted as an offer to purchase or sell any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Certain statements in this press release concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the “safe harbor” under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding lingering effects of the Covid-19 pandemic on our customers’ businesses, our ability to raise capital on any particular terms, fulfillment of customer orders, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, our ability to realize revenue from expanded operation and acquired assets in China and the U.S., our ability to attract and retain highly skilled professionals, client concentration, industry segment concentration, reduced demand for technology in our key focus areas, our ability to successfully complete and integrate potential acquisitions, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings. These filings are available at www.sec.gov. Dogness may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. In addition, please note that any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of the date of this press release. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

For more information, please contact Investor Relations:

Global IR Partners
David Pasquale
New York Office Phone: +1-914-337-8801
[email protected]



Posted on

SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China

–
SELLAS to Potentially R
eceive Up To $
202
Million, Inclusive of $7.5 Million
Upfront
License Fee and
$
8
Million
Near-term Milestone
s,
plus Tiered Royalties
–

–
3D Medicines to Lead Clinical Development and Commercialization of
G
P
S
and GPS+ 
in Greater China
–

– SELLAS
Retain
s
Rights in the Rest of World, Including U
nited
S
tates
–

NEW YORK and SHANGHAI, Dec. 07, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, and 3D Medicines Inc. (“3DMed”), a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, today announced that they have entered into an Exclusive License Agreement granting rights to 3DMed to develop and commercialize SELLAS’ lead late-stage clinical candidate, galinpepimut-S (GPS), as well as its next generation heptavalent immunotherapeuatic, GPS+, which is at preclinical stage, across all therapeutic and diagnostic uses in the Greater China territory (mainland China, Hong Kong, Macau and Taiwan). SELLAS retains sole rights to GPS and GPS+ outside of the Greater China area. Potential payments to SELLAS under the agreement could total $202 million in license fees and milestone payments, not including future royalties.

GPS is an innovative potentially first-in-class WT1-targeting artificially engineered synthetic heteroclitic immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. In 2020, SELLAS commenced a Phase 3 clinical trial (the REGAL study) of GPS in patients with acute myeloid leukemia (AML) who have reached second complete remission.

“This agreement represents an important achievement for SELLAS as we continue to progress our clinical development program for GPS. We are excited to collaborate with 3DMed on the development and commercialization of GPS in China. 3DMed, an ambitious biopharmaceutical company with development, registration and commercialization capabilities with a focus on developing next-generation immuno-oncology drugs and an experienced team, is a wonderfully complementary partner in bringing the potential of GPS to patients in Greater China. The collaboration begins to put in place essential elements designed to expand the reach of GPS outside the United States, following potential regulatory approvals,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.   “The completion of this agreement, amid the COVID-19 pandemic, shows the execution strength of our team. We are also pleased to have strengthened our balance sheet with the non-dilutive upfront license fee of $7.5 million with other potential milestones over the next several months.”

“We are very pleased to execute this exclusive license agreement of GPS and GPS+ in the Greater China area with SELLAS,“ said John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3DMed. “GPS and GPS+ are innovative therapeutics and, with growing need for new treatments, GPS’ potential use as a monotherapy as well as in combination with our Envafolimab, an innovative subcutaneous PD-L1 antibody which we have just filed for marketing approval in China, could create significant value for both 3DMed and SELLAS. This partnership highly reflects the vision of 3DMed to help patients with cancer to live longer and better. We believe that the addition of the GPS and GPS+ assets to our clinical portfolio is an important synergistic and strategic step for 3DMed as this partnership will expand our company’s therapeutic area expertise and improve our competitiveness.”

Under the financial terms of the agreement:

  • SELLAS could potentially receive up to $202 million in license and milestone payments during the course of the collaboration, not including future royalties.
  • SELLAS will receive payment of an upfront license fee of $7.5 million payable this quarter and is eligible to receive potential near-term milestones totaling up to an additional $8.0 million.
  • SELLAS is entitled to receive royalties on Chinese sales on a tiered basis, dependent on sales levels, ranging from the high single to low double-digit percentage.
  • 3DMed will be responsible for the costs of all development and regulatory activity for Greater China.

Torreya acted as a financial advisor to SELLAS.

About
Galinpepimut
-S

Galinpepimut-S (GPS) is an innovative and potentially first in class heteroclitic immunotherapy targeting Wilms Tumor 1 (WT1) which is ranked as the #1 cancer antigen by the National Cancer Institute.  GPS consists of a mixture of four peptide fragments derived from the WT1 whole-length protein, two of which are artificially mutated by design utilizing the heteroclitic technology principle, aiming at optimal immunogenicity and mitigation of immune tolerance by the vaccinated host.  GPS targets 25 carefully selected and validated WT1 antigenic epitopes and is applicable across the majority of HLA types on a global scale. GPS has an off-the-shelf lyophilized formulation and is administered subcutaneously to patients. GPS is optimally positioned either as a maintenance monotherapy in various clinical settings where the residual disease burden after prior debulking is very low, such as complete remission status in AML, or in combination with other therapeutic agents, most notably immune checkpoint inhibitors. In clinical trials, GPS has shown, both as monotherapy and in combination with checkpoint inhibitors, high rates of induction of immunogenicity and the abiitiy to delay disease relapse with an overall low incidence of adverse events, mainly low grade local inoculation reactions, and is currently being evaluated in a Phase 3 clinical trial as monotherapy for AML patients who are in second complete remission and in Phase 1 and Phase 2 studies in combination with checkpoint inhibitors. GPS was granted Orphan Drug Product Designations from the U.S. Food and Drug Administration (FDA), as well as Orphan Medicinal Product Designations from the European Medicines Agency, in AML, malignant pleural mesothelioma (MPM), and multiple myeloma (MM), as well as Fast Track Designation for AML, MPM, and MM from the FDA.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

About 3D Medicines
, Inc.

3D Medicines, Inc. is a biopharmaceutical company at the stage of late clinical development and early commercialization. With the concept “Help people with cancer live longer and better,” aiming for the future long-term survival of tumor patients, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, to help cancer patients live longer with better quality of life. 3D Medicines has built a pipeline with both innovative biological and small-molecule anti-tumor drugs, and a professional team with global development, registration and commercialization capabilities. For more information, please visit www.3d-medicines.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the Company’s plans for further development of and regulatory plans for GPS, including the timing of clinical results and the potential for GPS as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans and business strategy, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 13, 2020 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contacts

Adam Holdsworth
PCG Advisory
917-497-9287
[email protected]

Investor Relations
SELLAS Life Sciences Group, Inc.
917-438-4353
[email protected]



Posted on

Greek Government and Palantir Reaffirm Digital Transformation Partnership

Greek Government and Palantir Reaffirm Digital Transformation Partnership

DENVER–(BUSINESS WIRE)–
Alex Karp, the co-founder and CEO of Palantir Technologies (NYSE:PLTR), spoke via teleconference on December 3 with Greek Prime Minister Kyriakos Mitsotakis about Palantir’s ever-expanding partnership with the government of Greece to support their COVID-19 response efforts. Dr. Karp and Prime Minister Mitsotakis were joined by Palantir Executive Josh Harris and Kyriakos Pierrakakis, Minister of Digital Governance of Greece, to explore new ways to keep Greece ahead of the curve with their public health response.

Since the start of the pandemic, Palantir has worked with the Greek government to help enable data-driven decision-making in the context of the COVID-19 pandemic response. The government is leveraging Palantir’s Foundry software platform on top of Amazon Web Services infrastructure to deliver COVID-19 response workflows to government officials responding to the pandemic. Of particular value has been the deployment of a crisis-control center dashboard for the Prime Minister, which displays a holistic overview of the state of the COVID-19 pandemic in Greece in real time.

“Our partnership with the Greek government was borne out of necessity once the pandemic began,” said Alex Karp, co-founder and CEO of Palantir Technologies. “We have readily played a key role in their COVID-19 response effort, which from our experience has been one of the best in the world, and we look forward to broadening this partnership for years to come.”

The Ministry of Digital Governance, leading Greece’s rapid digital transformation, played a pivotal role in facilitating the partnership swiftly, enabling top decision makers to start generating actionable insights within a matter of days. As the pandemic continues to evolve, Palantir will deliver advanced integration and analytic capabilities to a range of government initiatives, to enable data-driven decision-making.

About Palantir

Palantir Technologies Inc. is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the partnership and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the partnership. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Lisa Gordon

[email protected]

KEYWORDS: Colorado Europe United States Greece North America

INDUSTRY KEYWORDS: Software Technology Networks Data Management

MEDIA:

Posted on

Next Milestone Ambition 2039: The global Mercedes-Benz supply chain is becoming CO2 neutral

PR Newswire

STUTTGART, Germany, Dec. 7, 2020 /PRNewswire/ —

  • As part of the Ambition 2039, Mercedes-Benz is pushing ahead with the transformation to CO2 neutrality with a package of measures along the entire value chain. The supplier network is a key element for achieving the climate goals of Mercedes-Benz due to the higher energy demand in the production of fully electric vehicles.
  • Markus Schäfer, Member of the Board of Management of Daimler AG and Mercedes-Benz AG; responsible for Daimler Group Research and Mercedes-Benz Cars COO: “With the electric EQS luxury sedan, which is already in the starting blocks for next year, we have already achieved important milestones in close cooperation with our partners – for example by purchasing CO2 neutrally produced battery cells. We are consequently pursuing this path: When awarding contracts for our subsequent electric vehicle platform – Mercedes-Benz Modular Architecture (MMA) for compact and medium-sized cars- we are already applying CO2 as a key criterion for the first time consistently.”
  • Gunnar Güthenke, Head of Procurement and Supplier Quality, Mercedes-Benz Cars: “Almost half of our approximately 2000 suppliers have signed an ‘Ambition Letter of Intent’ and are committed to supplying us with only CO2 neutral parts in the future. These companies account for more than half of the annual purchasing value of Mercedes-Benz AG.”

With Ambition 2039 Mercedes-Benz wants to offer a CO2 neutral new car fleet in less than 20 years. The transformation to electric mobility in particular increases the energy demand in the supply chain. Compared to a conventional combustion engine, the production of an all-electric vehicle is twice as CO2 intensive, mainly because of the lithium-ion batteries. Despite a higher energy demand in production, Mercedes-Benz plug-in hybrids and electric vehicles offer a clear advantage in terms of CO2 emissions compared to conventional drives already today, since only when the entire life cycle of the vehicles is considered a realistic picture emerges: Electric vehicles can make up for a large part of the initially higher CO2 emissions from the upstream value chain due to their emission-free driving. This is where Mercedes-Benz comes in and works with the global supplier network to reduce CO2 emissions in the production phase.

Markus Schäfer, Member of the Board of Management of Daimler AG and Mercedes-Benz AG; responsible for Daimler Group Research and Mercedes-Benz Cars COO: “Electric mobility and sustainability go hand in hand for Mercedes-Benz. With the electric EQS luxury sedan, which is already in the starting blocks for next year, we have already achieved important milestones in close cooperation with our partners – for example by purchasing CO2 neutrally produced battery cells. We are consequently pursuing this path: When awarding contracts for our subsequent electric vehicle platform – Mercedes-Benz Modular Architecture (MMA) for compact and medium-sized cars – we are already applying CO2 as a key criterion for the first time consistently.”

Key criterion for supplier selection

“Together with our partners, we are implementing the Mercedes-Benz Ambition 2039. Almost half of our approximately 2000 suppliers have signed an ‘Ambition Letter of Intent’ and are committed to supplying us with only CO2 neutral parts in the future. These companies account for more than half of the annual purchasing volume of Mercedes-Benz AG. This is an important proof point on the way to achieving our climate goals: our supplier network has also recognised the signs of the times, and is following the transformation. We place an additional focus on particularly CO2-intensive components and materials such as battery cells,” says Gunnar Güthenke, Head of Procurement and Supplier Quality, Mercedes-Benz Cars. “We are also in the process of setting up a tracking system that will enable us to see how CO2 emissions are reduced over time.” The company is in close dialogue with all other suppliers to jointly develop strategies for CO2 reduction.

Climate-neutrality is incorporated into contractual terms, and the Ambition Letter is a key criterion for awarding contracts. From 2039 at the latest, only production materials which are CO2 neutral in all value creation stages will be allowed through the factory gates of Mercedes-Benz. A supplier declining to sign the Ambition letter will not be taken into account for new supply contracts.

Focus on CO2-intensive components and materials

Mercedes-Benz will additionally focus on materials and components that are particularly CO2 intensive in manufacturing and processing until 2039. Focus components include battery cells, steel, and aluminium. These components account for about 80 percent of the CO2 emissions in the supply chain of a fully electric vehicle. Mercedes-Benz has already agreed on clear objectives with two strategic partners for battery cells: CATL (Contemporary Amperex Technology Co., Limited) and Farasis Energy have committed to supply battery cells that are produced using electricity from renewable sources such as hydropower, wind, and solar energy. This reduces the CO2 footprint of an entire battery by more than 30 percent. The rest of the supply chain will be included as a next step.

A holistic approach to environmental impact also includes the sustainable use of resources. The company’s goal is to consistently reduce the use of primary raw materials for electric drives by 2030 and gradually increase the share of secondary and renewable materials in vehicles. Mercedes-Benz is working with its partners to gradually increase the share of secondary material in the focus materials.

Mercedes-Benz plants as role model

Mercedes-Benz AG’s own plants, including the global battery production network, will produce on a CO2 neutral basis worldwide already from 2022. This will make them role models for the supplier network. In line with the procedure in Mercedes-Benz’s own plants, suppliers are required to avoid and reduce emissions as a fundamental principle. Only then can compensation via high-value projects be considered. The areas of approach for climate-neutral production are diverse, and range from reducing consumption to purchasing energy from renewable energy sources.

Ambition 2039: Climate-neutrality along the entire value creation chain

With its new strategy, Mercedes-Benz has introduced its claim to produce the world’s most desirable cars. Sustainability extends as a guiding principle across all strategic fields. The goal is a fully networked and completely CO2 neutral vehicle fleet. Ambition 2039 gives the direction for this along the entire value creation. The company aims to have plug-in hybrids or all-electric vehicles to make up more than 50% of its car sales by 2030. Major milestones include CO2 worldwide neutral production in all of Mercedes-Benz AG’s own plants from 2022, involvement in shaping the charging infrastructure and agreeing to specific CO2 measures with suppliers.

For more information on sustainability in the supply chain, see:

Next Milestone Ambition 2039: Mercedes-Benz sources battery cells from carbon-neutral production for the first time

High-volume battery supply supports “Electric First” strategy: Mercedes-Benz and CATL as a major supplier team up for leadership in future battery technology

Mercedes-Benz will in future only source battery cells with cobalt & lithium from certified mining sites, while significantly reducing cobalt

Daimler Supplier Award 2020: Daimler Honors Suppliers for the 12th Time: Sustainability Award Presented for the First Time

Mercedes-Benz AG at a glance
Mercedes-Benz AG is responsible for the global business of Mercedes-Benz Cars and Mercedes-Benz Vans with over 173,000 employees worldwide. Ola Källenius is Chairman of the Board of Management of Mercedes-Benz AG. The company focuses on the development, production and sales of passenger cars, vans and services. Furthermore, with its pioneering innovations, the company aspires to be a leader in the fields of connectivity, automated driving and alternative powertrains. The product portfolio comprises the Mercedes-Benz brand with the sub-brands Mercedes-AMG, Mercedes-Maybach and Mercedes me, as well as the smart brand and the EQ product and technology brand for electric mobility. Mercedes-Benz AG is one of the largest manufacturers of premium passenger cars. In 2019, it sold nearly 2.4 million passenger cars and more than 438,000 vans. In its two business segments, Mercedes-Benz AG is continually expanding its worldwide production network with over 40 production sites on four continents, while gearing itself to meet the requirements of electric mobility. At the same time, the company is constructing its global battery production network on three continents. Sustainable practice plays a decisive role in both business segments. To the company, sustainability means creating lasting value for all stakeholders: customers, employees, investors, business partners and society as a whole. The basis for this is Daimler’s sustainable business strategy. In this, the company takes responsibility for the economic, ecological and social effects of its business activities and looks at the entire value chain.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/next-milestone-ambition-2039-the-global-mercedes-benz-supply-chain-is-becoming-co2-neutral-301187302.html

SOURCE Daimler North America – Corporate Communications

Posted on

IIROC Trading Halt – LXR

Canada NewsWire

TORONTO, Dec. 7, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: LXRandCo, Inc.

TSX Symbol: LXR

All Issues: Yes

Reason: Pending News

Halt Time (ET): 8:05 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

Chipotle Unveils A Cozy Capsule Of Holiday Goods

New hoodies, joggers, beanies, and pajama sets are available for fans to snuggle up with this winter

PR Newswire

NEWPORT BEACH, Calif., Dec. 7, 2020 /PRNewswire/ — Chipotle Mexican Grill (NYSE: CMG) today announced it is launching its Holiday Goods line for the winter season. The collection includes comfy and trendy loungewear featuring minimalist Chipotle branding and made with 100% organic cotton.


The New Drop

These new threads are the perfect items to lounge in as fans enjoy their favorite Chipotle meals, which might be different than last year.

“Given all we’ve been through in 2020, this new line of Goods is the perfect way to do more of what we did best this year – staying inside and getting comfortable,” said Chris Brandt, Chief Marketing Officer. “We saw similar trends in our food as well, as digital orders have grown by more than 200% and our customers have eaten more ‘comfort’ foods with steak, burritos and Queso Blanco seeing major gains in 2020.”

Fans can also grab Chipotle’s 2020 wrapping kit featuring three different Chipotle-themed wrapping paper designs to add a fresh touch to all their holiday gifts:

https://chipotlegoods.com/collections/chipotle-goods/products/ch-f20agftbndl?variant=37698469036226

All profits from the Holiday Goods collection will go toward supporting organizations that are focused on making fashion or farming more sustainable.


Refreshed and Restocked

In August, Chipotle introduced Chipotle Goods, its first line of branded apparel which included responsibly sourced items like the open-looped avocado dye line that uses real avocado pits from Chipotle restaurants. For the upcoming holidays, Chipotle has restocked some of its Chipotle Goods items, including the previously sold out Natural Avocado Dye Tee.


Holiday Gift Cards


Chipotle holiday-themed egift cards are the perfect virtual stocking stuffer for the burrito-lovers on your list. Over the past year, Chipotle’s egift card sales have nearly tripled as consumers have increasingly pivoted to digital. Fans can learn more and purchase Chipotle holiday egift cards by visiting:

https://chipotlestore.wgiftcard.com/responsive/personalize_responsive/chooseDesign/chipotle_responsive/1

ABOUT CHIPOTLE
Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. Chipotle had over 2,700 restaurants as of September 30, 2020, in the United States, Canada, the United Kingdom, France and Germany and is the only restaurant company of its size that owns and operates all its restaurants. With more than 94,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. Steve Ells, founder and former executive chairman, first opened Chipotle with a single restaurant in Denver, Colorado in 1993. For more information or to place an order online, visit WWW.CHIPOTLE.COM.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chipotle-unveils-a-cozy-capsule-of-holiday-goods-301187295.html

SOURCE Chipotle Mexican Grill, Inc.

Posted on

Pakistan’s National Carrier PTCL Integrates Avaya With Its Digital Education Platform, QTaleem

Avaya Spaces™ innovation is enabling school administrators, teachers and students to deliver a 360-degree digital education experience.

PR Newswire

DUBAI, UAE, Dec. 7, 2020 /PRNewswire/ — GITEX Technology Week: Pakistan Telecommunication Company Limited (PTCL), one of the leading telecom and ICT services providers in Pakistan, has partnered with Avaya (NYSE: AVYA) on QTaleem, an online digital learning education platform and part of the PTCL Education Cloud solution offering.

Launching nationwide, PTCL QTaleem delivers a 360-degree digital education experience, enabling school administrators, teachers and students to be as productive online as they are on-campus. Being fully cloud-based, it delivers an end-to-end school management system, offering multitenancy, regional language support, quick installation and onboarding, and the ability to host live and recorded video classes.

Hosted on the secure PTCL TIA942 Rated-3 Data Center, PTCL QTaleem enables the delivery of an entire educational experience, from online training to support for boarding and operations, through a single window. The application-based platform will help to make learning more engaging, creating a holistic learning experience.

Speaking on the partnership, Zarrar Hasham Khan, Chief Business Services Officer, PTCL, said, “As a national carrier, PTCL is enabling an online education framework that has the potential to help more than 53 million students across the country. With this strategic partnership, we are able to address the current challenges facing the education sector in the country by bringing transformational change to delivering education, which is in line with Digital Pakistan.”

Speaking on the occasion, Nour El Atassi, Director, Service Providers – APAC, Middle East and Africa, Avaya, said, “Our partnership with PTCL brings a video collaboration solution to schools across Pakistan, enabling learning to take place anytime and anywhere. The current scenario has proved that the dissemination of knowledge is not dependent on a physical campus or traditional classroom. We look forward to supporting the country as it massively expands its reach of knowledge across the board.”

Avaya Spaces, the all-in-one video collaboration app for the digital workplace, integrates with PTCL’s QTaleem and enables the delivery of seamless video classes. This integration brings a campus-like experience to virtual classes, leveraging Avaya Spaces’ ability to centralize voice, video, messaging, chat and task management into a single application accessible through a desktop or mobile. This solution will facilitate educational institutions, both on- and off-campus, as they move towards blended education models.

 

Cision View original content:http://www.prnewswire.com/news-releases/pakistans-national-carrier-ptcl-integrates-avaya-with-its-digital-education-platform-qtaleem-301187293.html

SOURCE Avaya

Posted on

Slinger Bag Moves into Key Gulf States and Beyond

Slinger Bag Expands into Gulf Cooperation Council (GCC) Markets with Leading Sports Distributor Color Sports Inc.

BALTIMORE, Dec. 07, 2020 (GLOBE NEWSWIRE) — Slinger Bag (OTC: SLBG), the innovation-based sports brand focused on game improvement equipment for all ball sports, with an initial focus on the global tennis market, has today announced an exclusive five year distribution agreement with leading sports distributor, Color Sports Inc., to cover the Gulf States: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates (UAE). The exclusive agreement also includes other regional markets: Egypt, Tunisia, Pakistan, Maldives and Sri Lanka.

Operating across the Middle East, North Africa and South East Asia, Color Sports, Inc. is a sports specialist company, with over 30 years of experience in the sector, operating both a specialty sports distributor, brand licensee as well as an e-retailer. Color Sports already operates as a regional licensee for several key tennis brands and sees the addition of the exclusive Slinger Bag distribution as complementary to these as it fulfils its mission to bring the world’s best ball sports brands to the fast-growing markets within its remit.

Under the terms of the new partnership, Color Sports will be exclusive distributor of the exciting new, game-changing Slinger Bag tennis product in its designated territories and it expects consumer sales of Slinger Bag within these regions will commence by January 2021.

The new distribution agreement comes on the back of the recent bilateral normalization agreements signed by Israel, the UAE and Bahrain, which have begun to pave the way for the regional countries to forge new opportunities. Slinger Bag, which was founded in Israel, has capitalized on the huge uptick of interest for Israeli technology and products, and is one of the first Israeli-founded companies to announce distribution agreements that will encompass the whole region.

“We are very excited to represent Slinger Bag. More importantly, we are looking forward to this partnership and working together to promote tennis in these regions and perhaps helping produce future Grand Slam champions.” commented Rafi Farooqui, Director Color Sports, Inc.

Slinger Bag has taken the international tennis industry by storm since launching in Spring 2020, receiving widespread critical acclaim in the process. The product has quickly achieved distribution via a partner network on every continent and has surpassed order forecasts throughout the world.

Slinger Bag enables tennis enthusiasts to get out on court to play at any time without the need to find a playing partner – whether that be at their club, local park, on their driveways or in any other available open space. Slinger is designed to be lightweight, wheeled as a trolley bag and easily transported in the trunk of the smallest saloon or sedan car.

This proprietary design empowers players to set up and start launching balls within minutes, to control both the launch speed and the frequency of the balls using two customizable dials and vary the angle of elevation to suit groundstrokes, lobs or even, in the Ball Boy mode, to practice serves. Slinger Bag is lightweight at 15kg/33 lbs. and multi-functional, holding racquets and other gear, 72 tennis balls, and has pockets for storing wallets, keys, towel and a water bottle and is impressively affordable.

“We continue to rapidly expand the reach of Slinger to meet our increasing global demand and our association with Color Sports, who cover a wide territory base in depth, means that Slinger Bag will soon be available in these key and emerging tennis markets through one distributor relationship. Color Sports is a great partner for Slinger Bag for these important markets and brings with them tremendous market credibility and a strong passion and belief for our product and, as such, is uniquely positioned to provide Slinger Bag with the platform for our continued growth. said Mike Ballardie, CEO of Slinger Bag.

To find out more about Slinger Bag, visit https://slingerbag.com.

For the latest information on when Slinger Bag will be available in GCC and other regional markets please sign up using this form.

ENDS

For Investor Relations inquiries visit www.slingerbagir.com, or contact [email protected] or 443-407-7564

For U.K, Europe, New Zealand and Australia contact the UK Press Office, Joe Murgatroyd, [email protected], at Brand Nation, +44(0)207 940 7294

For U.S & CANADA., please contact the U.S. Press Office, Meryl Rader, [email protected], at CGPR, 908-528-3826

Slinger Bag Legal Counsel: Kalfa Law. Contact: [email protected]

About Slinger Bag®: Slinger® is a new sports brand focused on delivering innovative, game improvement technologies and equipment across all Ball Sport categories. With the vision to become a next-generation sports consumer products company, Slinger® enhances the skill and enjoyment levels of players of all ages and abilities. Slinger® is initially focused on building its brand within the global Tennis market, through its Slinger® Tennis Ball Launcher and Accessories. Slinger Bag® has underpinned its proof of concept with over $200M of retail value in global distribution agreements since the Spring of 2020. Led by CEO Mike Ballardie (former Prince CEO and Wilson EMEA racquet sports executive) Slinger® is now primed to continue to disrupt what are traditional global markets with its patent-pending, highly transportable and affordable Slinger® Launcher.

About Color Sports®

Operating across the Middle East, North Africa and South East Asia, Color Sports, Inc. is both a specialty sports distributor and e-retailer, and a racquet sports specialist, with over 30 years of experience in the sector. Color Sports’s mission is to bring the world’s best racquet sports brands to the fast growing markets in the region through its brand licenses.

Slinger Bag Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company’s products and services, the ability to complete development plans in a timely manner, changes in relationships with third parties, product mix sold by the Company and other factors described in the Company’s most recent periodic filings with the Securities and Exchange Commission, including its 2019 Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.



Posted on

Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting

– Lower rates of non-relapse transplant related mortality, sepsis, infections, and mucositis reported in patients receiving Iomab-B compared to patients on the control arm receiving salvage therapies

– Iomab-B enables high amounts of radiation to be delivered to the bone marrow to achieve targeted myeloablation

PR Newswire

NEW YORK, Dec. 7, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML) were presented at the 2020 American Society of Hematology (ASH) annual meeting. The oral presentation highlighted Iomab-B’s targeting ability and corresponding safety data from 110 patients from the SIERRA trial for which detailed safety data was available. Iomab-B targets CD45, an antigen expressed on leukemia and lymphoma cancer cells and immune cells including bone marrow stem cells but not cells outside of the blood forming or hematopoietic system. This allows high amounts of radiation to be delivered to the bone marrow via Iomab-B while sparing healthy organs. As a result, statistically significant lower rates of sepsis were reported as well as lower rates of febrile neutropenia, mucositis and non-relapse transplant related mortality in patients receiving Iomab-B and bone marrow transplant (BMT) compared to patients that received salvage therapy and a BMT. In addition, patients that crossed over to receive Iomab-B and went to BMT after receiving salvage therapy but not achieving a complete response also had lower rates of sepsis, febrile neutropenia, mucositis and non-relapse transplant related mortality.

Dr. Mark Berger, Actinium’s Chief Medical Officer, commented, “We are pleased that the engraftment and safety profile of Iomab-B remains positive and consistent with prior interim  safety results at 75% of patient enrollment in SIERRA and also consistent with the large body of historical data from Iomab-B. Collectively, this data gives excitement as we approach the upcoming ad hoc interim analysis for SIERRA that will be completed by year-end and the ultimate potential of Iomab-B for patients with R/R AML and other blood cancers as a targeted conditioning regimen.”

Safety data presented in ASH oral presentation are highlighted in the table below:

ASH Oral Presentation: High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia


Adverse Event


Received Iomab-
B/HCT (N=47)1
% (N)


No CR Crossed over to
Iomab-B/HCT (N=30)2 
% (N)


Achieved CR and
received Std HCT (N=9)
% (N)

Sepsis

4.3 (2)

22.2 (6)

33.3 (3)

Febrile Neutropenia
Gr 3-4

34.8 (16)

40.7 (11)

55.6 (5)

Mucositis Gr 3-4

10.9 (5)

18.5 (5)

33.3 (3)

Day +100 Non-
Relapse Mortality3

2/45

(4.4%)

3/26

(11.5%)

2/9

(22.2%)

1 Adverse Event data available for 46 of 47 evaluable patients

2 Adverse Event data available for 27 of 30 evaluable patients

3 Iomab-B arm: 4 patients unevaluable. Conventional Care Arm: 4 patients unevaluable

 


Patient Group


No. of
Patients


Radiation dose delivered to
the Marrow. Median (range)


Radiation dose to GI tract.
Median (range)

Iomab-B

47

14.9 Gy

(4.6-32)

2.8 Gy

(1.6-6.7)

Vijay Reddy, Vice President, Clinical Development and Head of BMT, “The targeted nature of Iomab-B makes it highly differentiated from current BMT conditioning regimens that are largely comprised of non-targeted cytotoxic chemotherapies. These data from SIERRA showing higher rates of sepsis, neutropenia and mucositis in patients receiving chemotherapy are consistent with the literature and unfortunately what we expected but hope to address with Iomab-B. Particularly, chemotherapy’s effect on the GI tract and resulting mucositis, which we believe is leading to the higher rates of sepsis seen in the control arm. We are highly encouraged by the lower rates of adverse events and the universal engraftment reported from SIERRA and excited for the potential of targeted conditioning could have an BMT access, patient outcomes and quality of life.”

About Iomab-B

Iomab-B (I-131 apamistamab) via the monoclonal antibody apamistamab, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells.  Apamistamab is linked to the radioisotope iodine-131 (I-131) and once attached to its target cells emits energy that travels about 100 cell lengths, destroying a patient’s cancer cells and ablating their bone marrow.  By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects of radiation on most healthy tissues while effectively killing the patient’s cancer and marrow cells.

Iomab-B is currently being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Relapsed or Refractory AML) trial, a 150-patient, randomized controlled clinical trial in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are age 55 and above.  The SIERRA trial is being conducted at preeminent transplant centers in the U.S. with the primary endpoint of durable Complete Remission (dCR) at six months and a secondary endpoint of overall survival at one year.  Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, in a potentially safer and more efficacious manner than the non-targeted intensive chemotherapy conditioning that is the current standard of care in bone marrow transplant conditioning.  A bone marrow transplant is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders.  Additional information on the Company’s Phase 3 clinical trial in R/R can be found at www.sierratrial.com.

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.  Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.  With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.  Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.  The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.  More information on this Phase 3 clinical trial can be found at www.sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell therapy and in a Phase 1/2 anti-HIV stem cell gene therapy with UC Davis.  In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.  Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.  Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.  This is where our intellectual property portfolio of over 130 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.  Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: www.actiniumpharma.com

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors:
Clayton Robertson
Actinium Pharmaceuticals, Inc.
[email protected]

Hans Vitzthum

LifeSci Advisors, LLC
[email protected]
(617) 430-7578

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-highlights-iomab-b-safety-data-presented-at-the-62nd-american-society-of-hematology-annual-meeting-301187100.html

SOURCE Actinium Pharmaceuticals, Inc.